|
Originally published In Press as doi:10.1074/jbc.M203471200 on June 19, 2002
J. Biol. Chem., Vol. 277, Issue 35, 31612-31622, August 30, 2002
Integrins 6A 1 and
6B 1 Promote Different Stages of
Chondrogenic Cell Differentiation*
Daniela
Segat ,
Riccardo
Comai ,
Eddi
Di Marco§,
Antonella
Strangio ,
Ranieri
Cancedda§¶,
Adriano T.
Franzi , and
Carlo
Tacchetti
From the Dipartimento di Medicina Sperimentale,
Sezione di Anatomia Umana, and ¶ Dipartimento Oncologia, Biologia
e Genetica, Universita' di Genova and the § Istituto
Nazionale per la Ricerca sul Cancro, Centro di Biotecnologie Avanzate,
Laboratorio Differenziamento Cellulare, 16100 Genova, Italy
Received for publication, April 10, 2002, and in revised form, June 3, 2002
 |
ABSTRACT |
The differentiation of chondrocytes and of
several other cell types is associated with a switch from the
6B to the 6A isoform of the laminin
6 1 integrin receptor. To define whether
this event plays a functional role in cell differentiation, we used an
in vitro model system that allows chick chondrogenic cells to remain undifferentiated when cultured in monolayer and to
differentiate into chondrocytes when grown in suspension culture. We
report that: (i) upon over-expression of the human 6B,
adherent chondrogenic cells differentiate to stage I chondrocytes
(i.e. increased type II collagen, reduced type I collagen,
fibronectin, 5 1 and growth rate, loss of
fibroblast morphology); (ii) the expression of type II collagen
requires the activation of p38 MAP kinase; (iii) the over-expression of
6A induces an incomplete differentiation to stage I
chondrocytes, whereas no differentiation was observed in
5 and mock-transfected control cells; (iv) a prevalence
of the 6A subunit is necessary to stabilize the
differentiated phenotype when cells are transferred to suspension
culture. Altogether, these results indicate a functional role
for the 6B to 6A switch in chondrocyte
differentiation; the former promotes chondrocyte differentiation, and
the latter is necessary in stabilizing the differentiated phenotype.
 |
INTRODUCTION |
Growth factors, cell-extracellular matrix
(ECM),1 and cell-cell
interactions are the primary determinants of lineage decisions and
differentiation events in embryogenesis. These regulatory events
involve different types of receptors and may lead to activation of
several signaling pathways, such as those mediated by MAP kinases (1-3). Changes in the expression pattern of most of these receptors, including the integrins (heterodimeric  receptors involved in cell-ECM and cell-cell interactions), are able to modulate several events associated with cell differentiation (3-20).
The onset of chondrogenesis in developing long bones is characterized
by the reduction of intercellular spaces and establishment of extensive
cell-cell contacts between mesenchymal chondrogenic cells,
i.e. cell condensation (21). Several factors have been shown
to play a role in this process, including cell-cell interactions (22-27), composition of the ECM (25, 28-30), changes in cell shape (31), and response to cytokines (32). Following cell condensation, chondrogenic cells that produce type I collagen, fibronectin (FN), and
its integrin receptor 5 1, differentiate
to stage I chondrocytes that express type II collagen and eventually to
stage II hypertrophic chondrocytes, characterized by type II and X
collagen production (12).
Most of these events can be reproduced in vitro in a tissue
culture model system that allows condensation and differentiation of
chick embryo tibiae chondrogenic cells (12, 33-35). These cells, which adhere to tissue culture dishes and display a
fibroblast-like phenotype (pre-chondrogenic cells), proliferate and
secrete type I collagen and FN. When transferred to suspension culture,
the cells rapidly aggregate and secrete type II collagen and other stage I chondrocyte-specific ECM molecules (12). In addition, differentiation is associated with: (i) down-regulation of type I
collagen, FN, and its receptor, 5 1
integrin; (ii) switch from the 6B to the
6A isoform of the integrin
6 1 receptor for laminin (LN); (iii)
reduced growth rate; and (iv) acquisition of a cobblestone morphology
when re-plated in monolayer culture (12, 25). In ~3 weeks of culture,
cell clusters are completely separated into single hypertrophic stage
II chondrocytes that express type X collagen (12, 36).
A switch from 6B to 6A has been
associated with the progression of cell differentiation of several cell
types and tissues (13, 37-39). The two alternatively spliced
isoforms of 6 differ in their cytoplasmic domain
(40-43) and, upon binding to LN, induce different levels of
phosphorylation of the signaling proteins paxillin and MAP kinases (44,
45). Furthermore, in cultured myoblasts, the ectopic expression of
6A 1 (19, 20) modulates functions that are
associated with differentiation and mitogenic responses, via MAP kinases.
The family of MAP kinases comprises several subtypes, including ERK-1
and -2 (extracellular signal-regulated kinases 1/2), JNK (c-Jun
N-terminal kinase or stress-activated protein kinase), and p38. Each
kinase subtype is activated by similar, but distinct, upstream kinases.
Extracellular stimuli appear to activate either single or multiple MAP
kinase pathways (46-48). In chondrocytes, inhibition of ERK1/2 and
activation of p38 are associated with differentiation in
vitro (49-51).
Here we have studied the role of the 6B to
6A switch, at the onset of chondrocyte differentiation,
by over-expressing 6A and 6B integrin
subunits in chondrogenic cells derived from chick embryo tibiae. We
have evaluated the effect on the expression of several differentiation
markers (cell morphology, growth rate, collagen expression pattern) in
cells grown under culture conditions that are either permissive or
nonpermissive for chondrocyte differentiation, i.e. cells
cultured in suspension or in monolayers.
Our results indicate a functional role for
6B 1 in the induction of chondrocyte
differentiation and for 6A 1 in its
progression. Furthermore, we suggest that these events depend on p38
MAP kinase activity.
 |
MATERIALS AND METHODS |
Antibodies--
The following antibodies to integrin subunits
were used: mouse monoclonal (mAb) BQ16 to human 6 (Dako, Glostrup,
Denmark); mouse mAb P1D6 to human 5 (Dako), mouse mAb V2E9 to avian
1 (Developmental Studies Hybridoma Bank, University of Iowa, Iowa City), and rabbit polyclonal antibodies to avian 2, 3, and 5 raised against their C-terminal regions (a gift from Prof. G. Tarone, Torino, Italy). The following antibodies to matrix proteins were used: mouse mAb B3/D6 to avian fibronectin (Developmental Studies
Hybridoma Bank); rabbit polyclonal antibodies to chick type I and type
II collagens (52); rabbit polyclonal antibody AS126.46 to laminin-1 (a
gift from Dr. R. Deutzmann, Regensburg, Germany). The following
secondary antibodies were used: donkey anti-rabbit (CyTM3), donkey
anti-mouse (FITC), and donkey anti-mouse (CyTM3) (Jackson
ImmunoResearch Laboratories, West Grove, PA); horseradish
peroxidase conjugate (HRP) and swine anti-rabbit and rabbit anti-mouse
immunoglobulins (Dako). For the MAP kinase assay the following
antibodies were used: rabbit polyclonal to p38 MAP kinase (Cell
Signaling Technology, New England Biolabs), rabbit polyclonal to
pATF-2 (Thr-71) (Cell Signaling Technology, New England Biolabs), and
mouse mAb AC-40 to actin (Sigma).
Cell Culture--
Primary cultures of chondrocytes were isolated
from chick embryo tibiae developed in virus-free eggs (Lohmann GMBH,
Cuxhaven, Germany) at stages 28-30 (53) as described previously
(34-36). Briefly, embryo tibiae were rinsed in phosphate-buffered
saline (PBS), pH 7.4, and digested with 400 units/ml collagenase I and 0.25% trypsin for 15 min at 37 °C to remove the perichondrium, including the putative perichondral ossification sleeve. The tissue debris was removed by centrifugation and the pellet digested for an
additional 45 min at 37 °C with the above mixture supplemented with
1000 units/ml collagenase II. Released chondrocytes were pooled,
harvested by low speed centrifugation, and resuspended in culture
medium (35).
Cells were grown in monolayer culture in Coon's modified
F-12 medium (Sigma) supplemented with 10% fetal calf serum, 50 units/ml penicillin-streptomycin and 2 mM
L-glutamine. The medium was changed every other day, and
confluent cells were split at a ratio of 1:3. After 12 days, cells were
transfected with the appropriate vector and then cultured in monolayer
for a maximum of 15-17 days. When required, the transfected cells were
released by trypsin treatment and transferred to anchorage-independent
conditions on a 1% agarose layer (35).
Construction of 6A, 6B, and
5 cDNAs--
All constructs were assembled in the
avian retroviral expression vector pSFCV-LE (54), a kind gift from B. Vennstrom (Department of Cell and Molecular Biology, Karolinska
Institute, Stockholm). Human wild type 6A (3177 bp) and
6B (3207 bp) cDNAs cloned into the pRC-CMV vector
(Invitrogen, Carlsbad, CA) were a kind gift from Dr. A. Sonnenberg
(Division of Cell Biology, The Netherlands Cancer Institute,
Amsterdam). The full-length cDNAs were isolated by digestion with
HindIII and subcloned into pSFCV-LE.
The human wild type 5 (3147 bp) cDNA, cloned in the
pECE vector, was a kind gift from Dr. E. Ruoslahti (Cancer Research
Center, The Burnham Institute, La Jolla, CA). The full-length cDNA
was isolated by digestion with SalI and XbaI and,
after Klenow treatment, inserted in-frame into the retroviral vector
linearized with EcoRV.
All constructs were checked by nucleotide sequencing using the ABI
PRISMTM DNA sequencing kits (PerkinElmer Life Sciences).
The following sequencing primers were used: the upstream
oligonucleotides 5'-ATGGGGAGCCGGACGCCAG-3' and
5'-GGATCCCGAGGGTTCCCTG-3' and the downstream oligonucleotides 5'-CCCGGGGGCCCCGAGAGTAC-3' and 5'-GGCATCAGAGGTGGCTGG-3' for the human 5 integrin; the upstream oligonucleotides
5'-TTCAACTTGGACACTCGG-3' and 5'-CTCGAGGTTATGGAACAGCAC-3' and the
downstream oligonucleotides 5'-GTAGACATACACTGCACCTCC-3' and
5'-CAATTACAGAAGTAGATC-3' for the human 6A isoform; and
5'-GTAGACATACACTGCACCTCC-3' and 5'-TGAGTAGCTTTCATTTCTG-3' for the
human 6B integrin isoform. The above sequences
correspond those published (40, 55, 56).
Transfection--
The empty pSFCV-LE vector or, alternatively,
the vector containing the full-length human cDNA of either
5, 6A, or 6B, was transfected into avian chondrogenic cells using polybrene and Me2SO. 24 h before transfection, 8 × 105-1 × 106 chondrogenic cells were
seeded in culture dishes. After 24 h, cells were rinsed with PBS
and resuspended in 3 ml of F-12 medium supplemented with 1% fetal calf
serum, 1% chicken serum, and 30 µg of polybrene. Ten µg of
circular plasmid DNA were admixed with the cells and incubated at
37 °C in 5% CO2 for 6 h with occasional agitation.
Cells were then incubated at room temperature with fresh medium and
30% Me2SO for 4 min, washed twice with PBS, and covered
with complete medium (Coon's modified F-12). Neomycin-resistant cells
were isolated by use of a selection medium containing G418 (500 µg/ml, Invitrogen) for 1 week. When indicated, cells were transferred
to suspension culture at day 10 of adherent culture to promote their
differentiation. Using this method, we obtained a much higher
transfection efficiency than with other protocols tested (not shown).
Flow Cytometry--
For flow cytometric analyses, transfected
cells were harvested with 2 mM EDTA in PBS, washed once in
PBS, and counted. 1 × 105 cells were incubated with
either a monoclonal antibody against human 6 (mAb-BQ16, diluted
1:20) or with a monoclonal antibody against human 5 (mAb-PID6,
diluted 1:20) for 20 min on ice. Cells were washed and incubated with a
donkey anti-mouse FITC-conjugated antibody (diluted 1:100) for 20 min
on ice. Finally, samples were washed twice in PBS and analyzed in a
FACScan using the CellQuest software (FACScalibur, BD PharMingen). This
analysis was performed on every new batch of transfected cells.
For the flow cytometric analysis of the endogenous levels of avian
integrin subunits 2 or 3, transfected cells were permeabilized with PBS, 0.1% saponin for 10 min at room temperature. Cells were then
incubated with antibodies to 2 (1:20) or 3 (1:5) diluted in PBS,
0.1% saponin and processed as described above. As a negative control,
transfected cells were incubated with the secondary antibody alone.
Each analysis was performed twice on two different batches of
transfected cells.
Immunofluorescence--
Immunofluorescence analyses
were performed routinely on each new batch of transfected cells.
At day 7 after transfection (end of the selection period), cells were
seeded on 10-mm glass coverslips and grown adherent for 2 days.
Coverslips were washed once with PBS and fixed for 10 min with 4%
paraformaldehyde at room temperature, rinsed in PBS, incubated with 30 mM NH4Cl, and permeabilized with PBS, 0.1%
saponin. Cells were subsequently incubated with primary antibodies to
detect the presence of type I collagen (1:400), type II collagen
(1:300), fibronectin (1:100), or laminin-1 (1:200) for 1 h at room
temperature. After being washed with PBS, cells were incubated with the
suitable secondary antibodies, i.e. anti-rabbit CyTM3
conjugate (1:200), or anti-mouse FITC conjugate (1:100). All antibodies
were diluted in PBS, 0.1% saponin. Nuclear staining was revealed by
4',6-diamidino-2-phenylindole (DAPI, 1:200, Sigma). Coverslips were
mounted using Moviol.
To determine the number of human 5 and 6 expressing cells at
early time points after transfection (day 2 and day 4), cells were
immunostained with primary antibodies to either human 6 (1:50) or
human 5 (1:25) and processed as described above. Analyses were
performed with an epifluorescence inverted microscope (Olympus Optical
Co.); images stored using a chilled Hamamatsu CCD black and
white camera and processed with IP-LAB and Adobe Photoshop software.
Ten epifluorescence microscope fields, obtained using a 40× lens, were
collected for each sample.
Evaluation of Apoptosis--
Cells were seeded on 10-mm glass
coverslips, transfected, and grown in the presence or absence of 10 µM p38 inhibitor, SB203580, as described below. After 2 and 4 days, cells were fixed with 4% formaldehyde at 4 °C, washed
several times with PBS, and permeabilized with 0.2% Triton X-100 for 5 min at room temperature. After several washes with PBS, apoptosis was
determined using the TUNEL method (TdT-mediated dUTP nick-end labeling)
(Promega) according to the manufacturer's instructions. Briefly, cells
were incubated at room temperature for 10 min with equilibration buffer
followed by a 1 h-incubation at 37 °C in a humidified chamber with
TdT diluted in the reaction buffer. The TdT reaction was stopped with 2× SSC for 15 min at room temperature, and cells were washed with PBS
and deionized water. Coverslips were mounted in Moviol, and apoptosis
was assessed and quantified by nuclear staining observed with an
epifluorescence inverted microscope. Ten fields, obtained using the
40× lens, were counted for each sample.
Type X Collagen and FN Metabolic Labeling--
Cells, cultured
either in monolayer or in suspension, were starved for 2 h at
37 °C in serum and methionine-free F-12 medium containing 100 µg/ml ascorbic acid. The medium was then supplemented with 100 µCi
of [35S]methionine (Amersham Biosciences) for 2 h at
37 °C. The culture medium was harvested and clarified by low speed
centrifugation. To evaluate type X collagen secretion, aliquots
containing 4 × 105 cpm of labeled medium were
dialyzed against 0.5 N acetic acid for 24 h at
4 °C, and proteins were digested with 100 µg of pepsin at 4 °C
for 12-15 h. The digested proteins were lyophilized, dissolved in
Laemmli reducing buffer, and separated by a 12.5% SDS-PAGE (57). The
radiolabeled proteins were detected by autoradiography with
HyperfilmTM MP (Amersham Biosciences).
To analyze the levels of secreted fibronectin in dedifferentiated
chondrocytes, aliquots of labeled medium containing 4 × 105 cpm were immunoprecipitated with the B3/D6 antibody in
the presence of the FN carrier (5 µg/ml) (Sigma) for 12 h
at 4 °C. Immunocomplexes were recovered with protein A-Sepharose,
washing the beads four times with IPP buffer (20 mM
Tris-HCl, 150 mM NaCl, 5 mM EDTA, 2% Nonidet
P-40, 0.2% SDS) containing the protease inhibitors (2 mM
phenylmethylsulfonyl fluoride (PMSF), 2 mM leupeptin, 2 mM pepstatin). Immunoprecipitates were analyzed by 6%
SDS-PAGE (57) under reducing conditions and detected by autoradiography with HyperfilmTM MP (Amersham Biosciences).
Immunoblots--
Cells obtained after different times of culture
under adherent or suspension conditions were pooled, washed with PBS,
lysed for 1 h in ice-cold buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Nonidet P-40) containing 2 mM PMSF
and 2% aprotinin as proteinase inhibitors, and centrifuged. The
protein concentration was determined using the Bradford dye
colorimetric assay (Bio-Rad, Hercules, CA). Samples containing 50-100
µg of total protein were separated by SDS-PAGE, blotted onto
nitrocellulose membranes, and analyzed by immunostaining. Membranes
were blocked with 3% nonfat dry milk in TBS, 0.05% Tween for 1 h
at room temperature and incubated with antibodies to type I (1:500) or
type II (1:250) collagen diluted in TBS, 0.05% Tween, 3% nonfat dry
milk for 1 h at room temperature. HRP-conjugated swine
anti-rabbit Ig (Dako) diluted at 1:2000 was used for detection. Reactivity was evaluated using a chemiluminescence emission assay (ECL,
Amersham Biosciences).
p38 Kinase Assay--
The activity of p38 was determined by an
immunocomplex kinase assay. Cell lysates from transfected cells
were cultured in the presence or absence of the p38 inhibitor
SB203580 (10 µM). The culture medium, containing
SB203580, was changed every 12 h. Cells were collected on days 2 and 4 after transfection (e.g. during the selection period).
Experiments were performed in parallel, with cells treated with the
same amount of Me2SO used to dilute the SB203580 inhibitor.
Cells were lysed in buffer containing 20 mM Tris-HCl, pH
7.5, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM -glycerolphosphate, 1 mM
Na3VO4, 1 µg/ml leupeptin, and 1 mM PMSF. The protein concentration was determined using the
Bradford dye colorimetric assay (Bio-Rad).
Samples containing 200 µg of total cell extract were precipitated
with immobilized phospho-p38 MAP kinase monoclonal antibody (Cell
Signaling Technology, New England Biolabs) and incubated with rotating
overnight at 4 °C. After two rinses with lysis buffer and kinase
buffer (25 mM Tris-HCl, pH 7.5, 5 mM
-glycerolphosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM
MgCl2), beads were resuspended in 50 µl of kinase buffer
supplemented with 200 µM ATP and 2 µg of ATF-2 fusion
protein and incubated at 30 °C for 30 min. The reaction was stopped
by the addition of 25 µl of 3× Laemmli sample buffer followed by
boiling. Samples were analyzed by SDS-PAGE and Western blot, by
probing the membranes with the phospho-ATF-2 antibody diluted 1:1000
overnight at 4 °C. Bound antibodies were detected as described above.
Furthermore, samples containing 200 µg of total cell extract were
separated by SDS-PAGE and analyzed by Western blot using antibodies to
either actin or p38 and type II collagen. The reaction was developed
using the ECL luminescence reagent.
Cell Surface Biotinylation--
Confluent chondrocytes at day 10 after transfection were starved in serum-free F12-medium for 30 min at
37 °C in 5% CO2. Cells were washed five times with
ice-cold buffer A (1.3 mM CaCl2, 0.4 mM MgS04 × 7 H20, 5 mM
KCl, 138 mM NaCl, 5.6 mM D-glucose,
25 mM Hepes, pH 7.4) and incubated twice for 15 min at
4 °C with 0.5 mg/ml Sulfo-NHS-biotin (Pierce) in buffer A. The
reaction was stopped with 0.1 M glycine, 0.3% BSA in
buffer A.
Cells were solubilized in ice-cold lysis buffer (20 mM
Tris-HCl, 150 mM NaCl, 5 mM EDTA, 2% Nonidet
P-40, 0.2% SDS) containing protease inhibitors (2 mM PMSF,
2 mM leupeptin, 2 mM pepstatin) and centrifuged
at 12,000 × g for 10 min at 4 °C. The supernatant was pre-cleared with protein A-Sepharose beads (Sigma) and normal rabbit serum (Sigma) in lysis buffer for 1 h at 4 °C,
centrifuged at 2,000 × g for 5 min at 4 °C, and
incubated with the specific antibody to chicken 1
integrin subunit (V2E9) overnight at 4 °C with gentle agitation.
Soluble immunocomplexes were bound to protein A-Sepharose beads (Sigma)
and recovered by centrifugation. After being washed with lysis buffer
and Pastan buffer (20 mM Tris-HCl, 100 mM NaCl,
1 mM EDTA, 0.5% Nonidet P-40, 2.5 M KCl), bound proteins were eluted with Laemmli buffer, boiled, separated by
6% SDS-PAGE, and blotted onto nitrocellulose membranes. Blots were
washed extensively with TBS-T (50 mM Tris-HCl, 150 mM NaCl, 0.05% Tween 20), blocked at room temperature for
1 h with 5% BSA in TBS-T, and incubated for 2 h at room
temperature with the primary antibody specific for avian
5 integrin subunits diluted in TBS-T, 5% BSA. After
three washes, membranes were incubated with the secondary antibodies
(Dako) diluted with TBS-T, 5%BSA (1:2000), washed extensively with
TBS-T and water, and developed using the ECL detection system.
For the detection of surface avian 1 expression,
membranes were incubated with streptavidin-horseradish peroxidase
(Amersham Biosciences), diluted in TBS-T, 5% BSA (1:2000). Filters
were developed using the ECL detection system.
Densitometric Analysis--
Autoradiographic films from Western
blot experiments were analyzed by calculating the total pixel value in
the area of interest using Kodak Digital Science 1D image analysis
software (Kodak, Rochester, New York).
 |
RESULTS |
Expression of 5, 6A, and
6B Integrin Subunits in Chondrogenic Cells--
We have
previously reported that chondrocyte differentiation in
vitro is associated with a down-regulation of the
5 1 fibronectin receptor and a switch from
the 6B to the 6A isoform of the
6 1 laminin receptor (25). These results
suggest that changes in the integrin expression pattern could be
relevant for the induction and/or progression of chondrocyte
differentiation. If this is the case, ectopic expression of either
6A or 6B should affect the
differentiation pattern of cells cultured either in monolayer (nonpermissive for differentiation) or in suspension (permissive for
differentiation) (36).
Consequently, we transiently transfected (day 0) avian chondrogenic
cells with full-length cDNAs coding for human 6A
(pSFCV-LE/ 6A) or 6B
(pSFCV-LE/ 6B) (40, 55) integrin subunits subcloned into
the pSFCV-LE avian retroviral expression vector (54). As a control, we
transfected 5 integrin subunit
(pSFCV-LE/ 5) (56) or the vector without an insert
(pSFCV-LE). 24 h after transfection (day 1), cells were
transferred into selective medium and cultured for 6 additional days
(day 7). Successful expression of the transfected subunits was
evaluated on day 7 by flow cytometry (Fig.
1).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 1.
Surface expression of human integrin
subunits 5,
6A and
6B in pSFCV-LE,
pSFCV-LE/ 5,
pSFCV-LE/ 6A, and
pSFCV-LE/ 6B adherent cells.
On day 7, pSFCV-LE, pSFCV-LE/ 5,
pSFCV-LE/ 6A, and pSFCV-LE/ 6B cells were
analyzed by flow cytometry using mAbs to human 5 or
6. In all panels, the thick lines correspond
to the indicated 5, 6A, and
6B transfectants and thin lines to the
control pSFCV-LE cells. The analysis was performed on each batch of
transfected cells. Data are from one representative experiment.
|
|
The expression of the human subunits could deplete the monomeric
1 pool available for endogenous integrins. To rule out this possibility, we surface-labeled transfected cells with biotin and
analyzed the cell lysates by immunoprecipitation with an antibody to
avian 1 followed by SDS-PAGE of precipitates,
electrophoretic transfer to nitrocellulose, and detection of
biotinylated integrins with streptavidin/HRP. 1
expression was 2-3-fold higher in cells transfected with vectors
expressing subunits than in control cells (pSFCV-LE) (Fig.
2A), suggesting that ectopic
expression of subunits induced a parallel over-expression of
endogenous 1 as described previously in other cell model
systems (20).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 2.
Surface expression of endogenous avian
1,
2, and
3 integrin subunits in pSFCV-LE,
pSFCV-LE/ 5,
pSFCV-LE/ 6A, and
pSFCV-LE/ 6B adherent cells.
A, cells cultured adherent for 10 days
were surface-biotinylated, lysed, and immunoprecipitated with avian
1 antibody (V2E9). The precipitates were
resolved by SDS-PAGE, blotted onto nitrocellulose membranes, and
stained with streptavidin/HRP. The level of the surface expression of
1 was evaluated by densitometry. Top line,
lane 1, pSFCV-LE; lane 2,
pSFCV-LE/ 5; lane 3,
pSFCV-LE/ 6A; lane 4,
pSFCV-LE/ 6B. Densitometric values are indicated by the
numbers below each lane. This gel represents one
of five independent experiments on different batches of transfected
cells. B, on day 7 pSFCV-LE, pSFCV-LE/ 5,
pSFCV-LE/ 6A, and pSFCV-LE/ 6B cells were
analyzed by flow cytometry using mAbs to avian 2 or
3 integrin subunits. In all panels, the gray
lines show the expression of 2 and 3
subunits and the black lines the negative controls (see
"Material and Methods"). The flow cytometry profiles show the
results of one of two experiments performed on two different batches of
transfected cells with similar results.
|
|
To exclude possible negative effects of the transfected subunits on the
expression of endogenous subunits, we evaluated by flow cytometry
the surface levels of chick 2 and 3 and
found that their levels were similar in all transfected cells (Fig. 2B). These results indicate that ectopic expression does not
affect endogenous integrins. Therefore, the effects that follow human 5 or 6 transfection are not due to a
reduced surface expression of endogenous integrins.
Transfection of 6 Reduces
5 1 and Fibronectin, but Not Laminin,
Expression--
In chondrogenic cells, fibronectin and laminin-1 are
the extracellular ligands for 5 1 and
6 1, respectively (25).
To assess whether transfection of ectopic subunits affects the
levels and distribution of FN and LN, immunofluorescence experiments
were performed after 10 days of adherent culture, using a polyclonal
antibody against the globular domains G3-G5 of laminin-1 or the B3/D6
monoclonal antibody against avian FN.
Staining for laminin was similar in all transfected chondrocytes,
showing a weak punctate distribution around the nucleus, which is
associated with a strong positive staining of focal contacts (Fig.
3A).

View larger version (55K):
[in this window]
[in a new window]
|
Fig. 3.
Fibronectin and
5 1,
but not laminin, are down-regulated upon ectopic
6 expression. A, pSFCV-LE,
pSFCV-LE/ 5, pSFCV-LE/ 6A, and
pSFCV-LE/ 6B cells from day 7 were plated on glass
coverslips and further cultured adherent for 3 days. Cells were
subsequently fixed, permeabilized, and immunostained with an antibody
to avian LN-1 followed by a Cy3-conjugated secondary antibody.
B, pSFCV-LE, pSFCV-LE/ 5,
pSFCV-LE/ 6A, and pSFCV-LE/ 6B cells from
day 7 were plated on glass coverslips and cultured adherent for three
additional days. Cells were subsequently fixed, permeabilized, and
immunostained with an antibody to avian FN followed by a donkey
anti-mouse FITC-conjugated antibody. Nuclear staining by
4',6-diamidino-2-phenylindole (asterisks) identifies single
cells. C, transfected cells were metabolically labeled with
35S on day 10. FN was immunoprecipitated from labeled
medium using the B3/D6 antibody to FN. Immunoprecipitates were analyzed
by SDS-PAGE under reducing conditions. D, surface expression
of the endogenous FN receptor, 5 1, was
determined by surface biotinylation of transfected cells. Cell lysates
were immunoprecipitated with the avian 1 antibody
(V2E9), separated by SDS-PAGE, and blotted onto nitrocellulose
membranes. Blots were detected with 5 antibody and
developed using the ECL system. Lane 1, pSFCV-LE;
lane 2, pSFCV-LE/ 5; lane
3, pSFCV-LE/ 6A; lane 4,
pSFCV-LE/ 6B. The experiment is representative of three
independent determinations performed on different batches of
transfected cells.
|
|
In contrast, we found that pSFCV-LE and pSFCV-LE/ 5 cells
displayed an extensive extracellular fibrillar network of FN underneath and between the cells (Fig. 3B), whereas
pSFCV-LE/ 6A and pSFCV-LE/ 6B cells showed
a faint staining with a few short fibrils (Fig.
3B).
To evaluate whether the reduced staining for FN was a consequence of a
lower level of synthesis and/or secretion, we metabolically labeled
transfected cells on day 10 and immunoprecipitated equal amounts of
culture medium with an antibody to FN. The results (Fig. 3C)
demonstrate a reduction in the levels of FN in all transfected cell
populations in comparison with pSFCV-LE cells. However, although pSFCV-LE/ 5 cells still secreted appreciable amounts of
FN, almost no signal was detected in pSFCV-LE/ 6 A and B. These results suggest that ectopic 6 inhibits FN
synthesis and secretion.
Because reduced levels of FN during chondrogenesis are associated with
a parallel down-regulation of the cognate
5 1 receptor (25), the levels of
endogenous 5 subunit were analyzed in the same cells.
Western blot analysis using an antibody specific for the chick
5 subunit demonstrated a significant reduction in the expression of this subunit in cells expressing either of the two 6 isoforms but not in pSFCV-LE and
pSFCV-LE/ 5 cells (Fig. 3D), which instead
gave a higher signal.
pSFCV-LE/ 6A and pSFCV-LE/ 6B Cells
Display Different Levels of Differentiation under Nonpermissive Culture
Conditions--
During chondrogenic differentiation, the
down-regulation of FN and 5 is associated with the loss
of other markers of undifferentiated cells (i.e. fibroblast
morphology, high proliferation rate, and type I collagen expression)
and the expression of stage I chondrocyte markers (i.e.
cobblestone morphology, low proliferation rate, and type II collagen
expression) (12, 25).
To evaluate the functional role of 6 in these events,
pSFCV-LE, pSFCV-LE/ 5, pSFCV-LE/ 6A, and
pSFCV-LE/ 6B cells were cultured in monolayer. When
observed by phase contrast microscopy on days 10 and 15, pSFCV-LE,
pSFCV-LE/ 5, and pSFCV-LE/ 6A cells
displayed a normal fibroblast-like phenotype. In contrast,
pSFCV-LE/ 6B cells exhibited a cobblestone-like
morphology (Fig.
4A); this phenotype is typical of stage I differentiated chondrocytes, which are
transferred to monolayer culture after differentiation in suspension
(35). Furthermore, at day 15 the number of both
pSFCV-LE/ 6A and pSFCV-LE/ 6B cells was
significantly lower compared with pSFCV-LE and
pSFCV-LE/ 5 cells (Fig. 4A). This observation
was confirmed by measuring the growth of the transfected cell
populations. We plated an equal number of cells on day 7 and counted
the cells on days 10, 15, and 17. At these three time points, 5-, 10-, and 20-fold fewer pSFCV-LE/ 6A and
pSFCVLE/ 6B cells were found in comparison with pSFCV-LE
and pSFCV-LE/ 5 cells (Fig. 4B).

View larger version (67K):
[in this window]
[in a new window]
|
Fig. 4.
Evaluation of chondrocyte differentiation
markers in transfected cells cultured in monolayer. A, phase
contrast microscopy of pSFCV-LE, pSFCV-LE/ 5,
pSFCV-LE/ 6A, and pSFCV-LE/ 6B cells. For
each new batch of transfected cells, an equal number of cells (5 × 104) was seeded, grown in monolayer for 10 or 15 days,
and photographed. B, growth curve of the different
transfected cells. The growth curve was determined at each new
transfection. Equal numbers (5 × 104) of cells were
seeded in triplicate on day 7 after transfection (day 0 of the
growth curve) and grown in monolayer for 10 additional days (day 10 of
the growth curve). Every other day, triplicate dishes of transfected
cells were trypsinized and counted using a Neubauer chamber. The graph
shows the mean number of transfected cells at each time point including
standard deviations. The drop in cell number, observed between day 0 and day 2 of the growth curve, is due to a loss of cells observed in
most cell lines after seeding (67). C, pSFCV-LE,
pSFCV-LE/ 5, pSFCV-LE/ 6A, and
pSFCV-LE/ 6B cells from day 7 were plated on glass
coverslips and cultured in monolayer for 3 additional days.
Immunofluorescence was performed on permeabilized cells using
antibodies to type I (Col. I) or type II (Col.
II) collagens followed by Cy3-conjugated secondary
antibodies.
|
|
Immunofluorescence experiments were conducted to analyze the pattern of
type I and II collagen expression. pSFCV-LE, pSFCV-LE/ 5, pSFCV-LE/ 6A, and pSFCV-LE/ 6B cells from
day 7 were plated onto coverslips for 2 additional days, fixed, and
permeabilized (Fig. 4C).
Control cells displayed an intracellular dotted and an extracellular
fibrillar staining pattern for type I collagen and either faint
(pSFCV-LE/ 5) or no staining (pSFCV-LE) for type II
collagen (Fig. 4C). pSFCV-LE/ 6A and
pSFCV-LE/ 6B cells instead exhibited strong intracellular
staining for type II collagen. In addition, pSFCV-LE/ 6Abut not pSFCV-LE/ 6B cells
displayed intracellular staining for type I collagen (Fig.
4C).
To quantify these data, we performed Western blot and densitometric
analysis of pSFCV-LE/ 6A and pSFCV-LE/ 6B
cells, finding that they expressed 2.52 ± 0.33- and 6.09 ± 0.648-fold more type II collagen, respectively, compared with
pSFCV-LE/ 5 (Fig. 5, Adh., Col. II). No type II collagen was expressed
by pSFCV-LE. On the contrary, type I collagen was produced by pSFCV-LE
and pSFCV-LE/ 5, and to a minor extent by
pSFCV-LE/ 6A, but it was undetectable in
pSFCV-LE/ 6B cells (Fig. 5, Adh., Col.
I).

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 5.
Pattern of collagen expression in transfected
cells growing either adherent or in suspension.
pSFCV-LE, pSFCV-LE/ 5, pSFCV-LE/ 6A, and
pSFCV-LE/ 6B cells from day 10 of adherent culture were
transferred to suspension culture for 24 h and then either lysed,
separated by SDS-PAGE and blotted onto nitrocellulose (Col.
I and Col. II), or labeled metabolically with
[35S]methionine, pepsin-digested, and separated by
SDS-PAGE (Col. X) (see "Materials and Methods"). Western
blots were developed with antibodies to either avian type I (Col.
I) or type II (Col. II) collagens. Pepsin-resistant
type X collagen bands, detected by autoradiography, were identified by
their size (molecular mass, 59 kDa). Data are from one
representative experiment of four from different batches of transfected
cells. Adh., cells cultured adherently, day 10;
Susp., cells cultured adherently for 10 days and then
transferred in suspension culture for 24 h.
|
|
Altogether, these data suggest that over-expression of
6B induces full differentiation of chondrogenic cells to
stage I chondrocytes under nonpermissive culture conditions. In
contrast, 6A-transfected cells synthesized type II
collagen and down-regulated FN and 5. However, they were
unable to modify other undifferentiated chondrogenic cell markers
(i.e. type I collagen and cell morphology). Finally, control
5-transfected cells did not display any change when
compared with pSFCV-LE, with the exception of a very low level of type II collagen expression.
Prevalence of 6A and 6B Is Necessary
to Stabilize the Differentiated Phenotype in Chondrocytes Suspension
Cultures--
The expression of type X collagen was determined to
evaluate whether ectopic expression of 6A and
6B is able to induce faster differentiation to stage II
chondrocytes under nonpermissive culture conditions. Lysates of
metabolically labeled cells were pepsin-digested and analyzed by
SDS-PAGE. Under these culture conditions neither the 6
nor the control transfected cells expressed type X collagen (Fig. 5,
Adh., Col. X).
We next evaluated whether 6A and 6B
subunits play any role in the progression from stage I to stage II
chondrocytes in culture conditions permissive for differentiation
(i.e. suspension cultures). Although in such cultures type X
collagen is produced first after several days,
pSFCV-LE/ 6A and pSFCV-LE/ 6B cells
expressed type X collagen after only 24 h (Fig. 5,
Susp., Col. X). This was due specifically to the
over-expression of the 6 subunits, demonstrated by the
absence of type X collagen after 24 h of suspension culture in
pSFCV-LE and pSFCV-LE/ 5 (Fig. 5, Susp.,
Col. X). Levels of type II collagen expression were also
analyzed and, as anticipated, were found to be increased in
pSFCV-LE/ 6A, pSFCV-LE/ 5, and pSFCV-LE. In
contrast, no type II collagen was expressed by
pSFCV-LE/ 6B (Fig. 5, Susp., Col.
II), and type I collagen was almost undetectable in all samples
(Fig. 5, Susp., Col. I). These results suggest that a prevalence of 6A versus
6B is necessary to maintain the stage I-differentiated phenotype.
p38 Kinase Activation Is Necessary for
6-induced Chondrocyte Differentiation--
p38 MAP
kinase activation is associated with differentiation of chondrogenic
cells (50, 51, 58, 59) and myoblasts (19, 20) in culture. The activity
of p38 was determined in early phases of chondrocyte differentiation
induced by 6B transfection, with the aim of identifying
the earliest events associated with differentiation to stage I
chondrocytes. At early time points after chondrocyte transfection (days
2 and 4, before selection was completed), p38 activity was evaluated by
measuring the levels of phosphorylated ATF-2, a major phospho-p38
kinase substrate. Equal amounts of total lysate proteins were
immunoprecipitated with an antibody to p-p38.
Immunoprecipitates were then incubated with ATF-2 fusion protein in the
presence of ATP, thus allowing immunoprecipitated active p38 MAP kinase
to phosphorylate ATF-2. Phosphorylation of ATF-2 at Thr-71 was detected
by Western blotting using a phospho-ATF-2 (Thr-71) antibody. In
addition, the total amount of p38 was also measured in each cell
population by Western blot of total lysates. A densitometric analysis
was performed, and the data for each sample were normalized to the
actin and p38 contents. Values were further corrected for the number of cells expressing the ectopic subunits as determined by
immunofluorescence. The results indicate that p38 activity on
day 2 is 2.56 ± 0.251 and 4.07 ± 0.266 times higher in
pSFCV-LE/ 6A and pSFCV-LE/ 6B cells,
respectively, in comparison with control cells (pSFCV-LE) (Table
I).
View this table:
[in this window]
[in a new window]
|
Table I
Analysis of p38 MAP kinase activity: level of ATF-2
Levels of p-ATF-2 in transfected cells (pSFCV-LE,
pSFCV-LE/ 5, pSFCV-LE/ 6A, and
pSFCV-LE/ 6B) on days 2 and 4 were determined by
densitometric analysis of the gel shown in Fig. 6A (ATF-2).
Values were normalized first for p38 and actin levels determined by
densitometry (Fig. 6A). Values obtained were subsequently
normalized for the percentage of positive cells giving the average
ATF-2 phosphorylation level/cell. Data are from one representative
experiment of three.
|
|
On the contrary, on day 2 the pSFCV-LE/ 5 cells displayed
50% of the p38 activity detected in control cells (pSFCV-LE) (Table I,
Fig. 6A). These results
demonstrate that high levels of p38 activation are dependent on the
expression of ectopic 6B.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 6.
Analysis of p38 MAP kinase
activity and its role in type II collagen expression. Cells were
cultured in the absence (A) or presence (B) of
SB203580, a p38 inhibitor. For ATF-2, equal amounts of cell
extracts from pSFCV-LE (lane 1),
pSFCV-LE/ 5 (lane 2),
pSFCV-LE/ 6A(lane 3), and
pSFCV-LE/ 6B (lane 4) cells were analyzed on
days 2 and 4. p38 activity was determined using an in vitro
kinase assay and ATF-2 as a substrate. The levels of ATF-2 were
determined by Western blot using an antibody to pATF-2.
Equal amounts of total cell extracts from day 2 and 4 were analyzed by
Western blot using an antibody to p38. For actin, equal amounts of
total cell extracts from days 2 and 4 were analyzed by Western blot
using an antibody to actin. For p38/cells, the total amount of
p38/cell was determined. The results were evaluated by dividing the
p38/actin ratio normalized to the number of cells expressing ectopic
subunits as determined by immunofluorescence. This value ranged
between 52 and 69% of the whole cell population. C,
total extracts from pSFCV-LE (lane 1),
pSFCV-LE/ 5 (lane 2),
pSFCV-LE/ 6A(lane 3), and
pSFCV-LE/ 6B (lane 4) cells cultured in the
absence (top) or presence (bottom) of SB203580
(10 µM). Cells were collected on days 2 and 4, and equal
amounts of cell extracts were analyzed by Western blot with an antibody
to type II collagen. Data are from one representative experiment of
three, using different batches of transfected cells.
|
|
To address a possible role for p38 in the differentiation events
associated with ectopic 6 expression, we first inhibited p38 activity using the specific inhibitor SB203580 (69). As expected,
addition of 10 µM SB203580 to the culture medium of transfected cells had no effect on the expression of total p38, but it
drastically reduced the level of p-ATF-2 (Fig.
6B). In addition, the number of apoptotic cells was
determined by analyzing the nuclear TUNEL staining using
epifluorescence microscopy. No significant differences were found
between the treated and nontreated cells (data not shown).
Next, the amount of type II collagen synthesized on days 2 and 4 (Fig.
6C) in the presence or absence of SB203580 was determined. Western blot analyses of cell lysates from all of the transfected cell
populations (pSFCV-LE, pSFCV-LE/ 5,
pSFCV-LE/ 6A, and pSFCV-LE/ 6B) showed that
on day 4, in the absence of the p38 inhibitor, only pSFCV-LE/ 6B synthesized type II collagen. The addition
of SB203580 to the culture medium abolished such expression. It is
notable that type II collagen is detected on day 10 in
6A-transfected cells only (day 10, Fig. 4). These
results suggest that a functional correlation exists between p38
activation and expression of a stage I chondrocyte differentiation
marker induced by 6B over-expression.
 |
DISCUSSION |
A switch in expression from the 6B to the
6A isoform of the 6 1
laminin receptor is associated with differentiation in several cell
types (37-39). The two alternatively spliced isoforms of
6 differ in their cytoplasmic domains, which consist of
36 and 54 amino acids in 6A and 6B
(40-43), respectively, and display similar binding affinities and
ligand specificities. Moreover, upon phorbol ester treatment, only the
6A isoform is phosphorylated (41, 60). Differential
interactions with cytoskeletal proteins have been suggested to explain
the greater ability of 6A to induce pseudopodia
formation and to promote migration in a macrophage cell line plated on
a laminin-1 (19, 44, 61). However, little is known about the roles
played by 6A and 6B in the modulation of
cell differentiation. We have addressed this question using an in
vitro model system that allows differentiation of chondrogenic cells transferred from nonpermissive (adherent) to permissive (suspension) culture conditions. The in vitro chondrocyte
differentiation from pre-chondrogenic cells to stage I chondrocytes
(33, 35) is associated with a switch from the 6B to the
6A (25). Our approach has been to over-express the two
alternative isoforms, evaluating the effect on chondrocyte
differentiation under both nonpermissive and permissive culture conditions.
6B Expression Promotes Full Differentiation to Stage
I Chondrocytes--
Under nonpermissive culture conditions, ectopic
expression of the 6B isoform is sufficient to
specifically promote chondrocyte differentiation to stage I, as
indicated by activation of the expression of type II collagen,
reduction of the growth rate, reduction of type I collagen, fibronectin
and 5 1 expression, and changes in cell
morphology from a fibroblast-like to a cobblestone shape.
The specificity of the 6B effects listed above is
supported by the observation that transfection with human
6A or 5 subunits only prompts a low level
and delayed expression of type II collagen. Furthermore, there is no
loss of markers of the undifferentiated phenotype.
The full differentiation to stage I chondrocyte following
6B transfection is not due to a nonspecific imbalance in
the expression of endogenous chick integrins. This is demonstrated by
the unchanged levels of chick 2 and 3
after transfection of either human 6 or
5.
On the contrary, the specific 6-dependent
reduction of chick 5 may contribute to the
differentiation process by removing the inhibitory activity exerted by
5 1 (62). The reduction in endogenous
5 is a direct and specific effect of 6
transfection and is not observed when cells are transfected with
5. In addition, it occurs despite the increased levels
of endogenous 1, which provide sufficient protein to
assemble chick 5 1 heterodimers.
6A Prevalence Is Necessary to Fully Maintain the
Stage I Differentiation State--
Upon differentiation to stage I
chondrocytes, the switch from expression of 6B to
6A leads to a prevalence of the latter on the cell
surface. Experiments to impair this were performed by over-expressing
6B.
6B-transfected chondrocytes, when differentiated in
adherent cultures, are unable to maintain their phenotype once
transferred in suspension, as shown by loss of expression of type II
collagen. In contrast, 6A, 5, and
mock-transfected cells differentiate normally to stage I.
These results suggest that the prevalence in 6A surface
expression during chondrogenesis may contribute to sustaining the differentiated phenotype. In addition, upon transfection of
6B differentiation to stage II chondrocyte progresses
normally in vitro. These observations suggest that other
events may contribute to support the chondrocyte phenotype in
vivo. Therefore, it is likely that transition to stage II
chondrocytes implies several independent events, one of which may be
the role of 6A in sustaining type II collagen expression.
Stage I to Stage II Transition Requires Suspension Culture and
6 to Occur--
To assess whether 6B
and/or 6A are involved in the progression from stage I
to stage II chondrocyte differentiation, the expression of type X
collagen was evaluated in transfected cells cultured either in
monolayer or in suspension.
We found that type X collagen is exclusively expressed in suspension
cultures but that it appears earlier (24 h) in both types of
6-transfected cells as compared with control cells where
several days are required. These results further suggest that neither of the 6 subunits is sufficient to promote
differentiation to stage II chondrocytes and that other conditions
associated with culture in suspension are necessary. In addition, this
further step of differentiation is likely to be independent from the
expression of type II collagen, as shown by the behavior of
6B-transfected cells.
Early Activation of the p38 MAP Kinase Pathway Is Functionally
Associated with 6B-induced Type II Collagen
Expression--
p38 MAP kinase has been shown to modulate chondrogenic
differentiation. Growth/differentiation factor-5 (GDF-5) induces p38 activation and chondrocyte differentiation in the mouse chondrogenic cell line ATDC5 (49). Chun and co-workers (50, 51, 58, 59), using a
micromass culture system, have shown that chondrocyte differentiation associates with a protein Kinase C (PKC)-independent activation of p38 in chondrogenesis. In addition, treatment of micromass cultures with epidermal growth factor, a limb bud cartilage development modulator, decreases the rate of chondrogenesis by reducing
p38 activity (51).
Furthermore, adhesion to substrates and actin cytoskeletal organization
have been shown to be important in integrin/growth factor receptor
signaling via MAP kinases (2, 63-66). These pathways may be relevant
to the induction of chondrocyte differentiation in
anchorage-independent cultures (12) and following cytochalasin D
treatment (31).
Here we show that inhibition of p38 activation by SB203580 inhibits
induction of type II collagen expression by 6B.
Therefore it appears that this signaling pathway is involved in
chondrocyte differentiation. In addition, by determining the level and
time of p38 activity we found a peak at day 2 in 6B
transfected cells, which was about 2-fold higher than the levels
measured on days 2 and 4 in 6A- and
5-transfected cells. These results correlate with the
early expression of type II collagen in 6B but not in 6A- and 5-transfected cells.
Although these data do not allow us to conclude that p38
activation is directly dependent on 6B, they suggest
that p38 activation is functionally related with type II collagen expression.
The presence of LN in chondrogenic area of the condensing mesenchyme
suggests that the interaction of 6B 1
receptor may be relevant in vivo, as well as in
vitro. In addition, in in vitro model systems more
closely reproducing the limb bud chondrogenic area, i.e.
micromass cultures, the inhibition of p38 activity has been proven to
block type II collagen expression (50), further supporting this hypothesis.
The interpretation of the relevance of 6A role in
vivo is more complex. The presence of LN in the ECM surrounding
stage II chondrocytes in cartilage tissue (67), suggests that its
interaction with 6A 1 may play a role in
chondrocyte differentiation in vivo, as we have highlighted
in vitro. However, mice deficient in 6A do
not display defective endochondral bone formation (68), suggesting that
the potential role of 6B 1-LN interactions
is not sufficient to promote the progression of chondrocyte
differentiation and that other events may be relevant to this process.
In particular, further studies are needed to address the role of other
cell-ECM interactions and soluble factor effects.
In conclusion, our results demonstrate that ectopic expression of the
6B 1 laminin receptor is sufficient to
promote differentiation of chondrogenic cells even under nonpermissive
culture conditions. Furthermore the expression of 6A
contributes to stabilizing the differentiated phenotype and to
sustaining the progression to further steps of chondrocyte
differentiation in vitro.
 |
ACKNOWLEDGEMENTS |
We thank Patrizio Castagnola, Ivan Matteo de
Curtis, Carlo E. Grossi, Ruggero Pardi, Mats Paulsson, Neil R. Smyth,
and Caterina Valetti for critical reading of the manuscript and helpful
discussions and Armando Di Donato for helpful discussion on MAP
kinases. We are also grateful to R. Deutzmann, E. Ruoslahti, A. Sonnenberg, G. Tarone, and B. Vennstrom for the generous gift of
reagents. The help of D. Saverino in the flow cytometry analysis and of N. Sessarego in tissue culture is greatly appreciated. The monoclonal antibodies V2E9 and B3D6 were developed, respectively, by Dr. A. F. Horwitz, University of Illinois, and Dr. D. Fambrough, Johns Hopkins University.
 |
FOOTNOTES |
*
This work was supported by grants from MURST (PRIN
projects) and CNR (Target project Biotechnology) (to C. T.). The
monoclonal antibodies V2E9 and B3D6 were obtained, respectively, from
the Developmental Studies Hybridoma Bank, maintained at the Department of Pharmacology and Molecular Sciences, Johns Hopkins University School
of Medicine, Baltimore, and the Department of Biological Sciences,
University of Iowa, Iowa City, under contract NO1-HD-2-3144 from the
NICHD, National Institutes of Health.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dipartimento di
Medicina Sperimentale, Sezione di Anatomia Umana, Università di
Genova, Via de Toni, 14 16100 Genova, Italy. Tel.: 39-0103537864; Fax:
39-0103537885; E-mail: carlo.tacchetti@unige.it.
Published, JBC Papers in Press, June 19, 2002, DOI 10.1074/jbc.M203471200
 |
ABBREVIATIONS |
The abbreviations used are:
ECM, extracellular
matrix;
MAP, mitogen-activated protein;
FN, fibronectin;
LN, laminin;
ERK, extracellular signal-regulated kinase;
JNK, c-Jun N-terminal
kinase;
mAb, monoclonal antibody(s);
FITC, fluorescein isothiocyanate;
HRP, horseradish peroxidase;
PBS, phosphate-buffered saline;
TUNEL, TdT-mediated dUTP nick-end labeling;
PMSF, phenylmethylsulfonyl
fluoride;
TBS, Tris-buffered saline;
BSA, bovine serum albumin.
 |
REFERENCES |
| 1.
|
Schwartz, M. A.,
and Ingber, D. E.
(1994)
Mol. Biol. Cell
5,
389-393[Abstract]
|
| 2.
|
Aplin, A. E.,
Howe, A. K.,
and Juliano, R. L.
(1999)
Curr. Opin. Cell Biol.
11,
737-744[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Boudreau, N. J.,
and Jones, P. L.
(1999)
Biochem. J.
339,
481-488
|
| 4.
|
Plopper, G. E.,
McNamee, H. P.,
Dike, L. E.,
Bojanowski, K.,
and Ingber, D. E.
(1995)
Mol. Biol. Cell
6,
1349-1365[Abstract]
|
| 5.
|
Rana, B.,
Mischoulon, D.,
Xie, Y.,
Bucher, N. L.,
and Farmer, S. R.
(1994)
Mol. Cell. Biol.
14,
5858-5869[Abstract/Free Full Text]
|
| 6.
|
Dike, L. E.,
and Ingber, D. E.
(1996)
J. Cell Sci.
109,
2855-2863[Abstract]
|
| 7.
|
Boudreau, N.,
Werb, Z.,
and Bissell, M. J.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
3509-3513[Abstract/Free Full Text]
|
| 8.
|
Bottazzi, M. E.,
Zhu, X.,
Bohmer, R. M.,
and Assoian, R. K.
(1999)
J. Cell Biol.
146,
1255-1264[Abstract/Free Full Text]
|
| 9.
|
Assoian, R. K.,
and Zhu, X.
(1997)
Curr. Opin. Cell Biol.
9,
93-98[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Zhu, X.,
Scharf, E.,
and Assoian, R. K.
(2000)
J. Biol. Chem.
275,
6703-6706[Abstract/Free Full Text]
|
| 11.
|
Roovers, K.,
and Assoian, R. K.
(2000)
Bioessays
22,
818-826[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Cancedda, R.,
Descalzi Cancedda, F.,
and Castagnola, P.
(1995)
Int. Rev. Cytol.
159,
265-358[Medline]
[Order article via Infotrieve]
|
| 13.
|
Walker, J. L.,
and Menko, A. S.
(1999)
Dev. Biol.
210,
497-511[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Kadoya, Y.,
Kadoya, K.,
Durbeej, M.,
Holmvall, K.,
Sorokin, L.,
and Ekblom, P.
(1995)
J. Cell Biol.
129,
521-534[Abstract/Free Full Text]
|
| 15.
|
Hay, E. D.
(1981)
J. Cell Biol.
91,
205s-223s[Free Full Text]
|
| 16.
|
Lin, C. Q.,
and Bissell, M. J.
(1993)
FASEB J.
7,
737-743[Abstract]
|
| 17.
|
Streuli, C. H.,
Bailey, N.,
and Bissell, M. J.
(1991)
J. Cell Biol.
115,
1383-1395[Abstract/Free Full Text]
|
| 18.
|
Cirulli, V.,
Beattie, G. M.,
Klier, G.,
Ellisman, M.,
Ricordi, C.,
Quaranta, V.,
Frasier, F.,
Ishii, J. K.,
Hayek, A.,
and Salomon, D. R.
(2000)
J. Cell Biol.
150,
1445-1460[Abstract/Free Full Text]
|
| 19.
|
Sastry, S. K.,
and Horwitz, A. F.
(1996)
Dev. Biol.
180,
455-467[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Sastry, S. K.,
Lakonishok, M., Wu, S.,
Truong, T. Q.,
Huttenlocher, A.,
Turner, C. E.,
and Horwitz, A. F.
(1999)
J. Cell Biol.
144,
1295-1309[Abstract/Free Full Text]
|
| 21.
|
Maini, P. K.,
and Solursh, M.
(1991)
Int. Rev. Cytol.
129,
91-133[Medline]
[Order article via Infotrieve]
|
| 22.
|
Solursh, M.,
and Reiter, R. S.
(1980)
Dev. Biol.
78,
141-150[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Jiang, T. X., Yi, J. R.,
Ying, S. Y.,
and Chuong, C. M.
(1993)
Dev. Biol.
155,
545-557[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Tacchetti, C.,
Simonneau, L.,
Thiery, J. P.,
and Levi, G.
(1992)
Eur. J. Cell Biol.
57,
236-243[Medline]
[Order article via Infotrieve]
|
| 25.
|
Tavella, S.,
Bellese, G.,
Castagnola, P.,
Martin, I.,
Piccini, D.,
Doliana, R.,
Colombatti, A.,
Cancedda, R.,
and Tacchetti, C.
(1997)
J. Cell Sci.
110,
2261-2270[Abstract]
|
| 26.
|
Oberlender, S. A.,
and Tuan, R. S.
(1994)
Development
120,
177-187[Abstract]
|
| 27.
|
Tavella, S.,
Raffo, P.,
Tacchetti, C.,
Cancedda, R.,
and Castagnola, P.
(1994)
Exp. Cell Res.
215,
354-362[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Dessau, W.,
von der Mark, H.,
von der Mark, K.,
and Fischer, S.
(1980)
J. Embryol. Exp. Morphol.
57,
51-60[Medline]
[Order article via Infotrieve]
|
| 29.
|
Mackie, E. J.,
Thesleff, I.,
and Chiquet-Ehrismann, R.
(1987)
J. Cell Biol.
105,
2569-2579[Abstract/Free Full Text]
|
| 30.
|
Maleski, M. P.,
and Knudson, C. B.
(1996)
Exp. Cell Res.
225,
55-66[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Zanetti, N. C.,
and Solursh, M.
(1984)
J. Cell Biol.
99,
115-123[Abstract/Free Full Text]
|
| 32.
|
Chang, S. C.,
Hoang, B.,
Thomas, J. T.,
Vukicevic, S.,
Luyten, F. P.,
Ryba, N. J.,
Kozak, C. A.,
Reddi, A. H.,
and Moos, M., Jr.
(1994)
J. Biol. Chem.
269,
28227-28234[Abstract/Free Full Text]
|
| 33.
|
Tacchetti, C.,
Quarto, R.,
Nitsch, L.,
Hartmann, D. J.,
and Cancedda, R.
(1987)
J. Cell Biol.
105,
999-1006[Abstract/Free Full Text]
|
| 34.
|
Tacchetti, C.,
Quarto, R.,
Campanile, G.,
and Cancedda, R.
(1989)
Dev. Biol.
132,
442-447[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Castagnola, P.,
Moro, G.,
Descalzi-Cancedda, F.,
and Cancedda, R.
(1986)
J. Cell Biol.
102,
2310-2317[Abstract/Free Full Text]
|
| 36.
|
Castagnola, P.,
Dozin, B.,
Moro, G.,
and Cancedda, R.
(1988)
J. Cell Biol.
106,
461-467[Abstract/Free Full Text]
|
| 37.
|
Jiang, R.,
and Grabel, L. B.
(1995)
Exp. Cell Res.
217,
195-204[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Cooper, H. M.,
Tamura, R. N.,
and Quaranta, V.
(1991)
J. Cell Biol.
115,
843-850[Abstract/Free Full Text]
|
| 39.
|
Morini, M.,
Piccini, D.,
Barbieri, O.,
and Astigiano, S.
(1997)
Exp. Cell Res.
232,
304-312[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Hogervorst, F.,
Kuikman, I.,
van Kessel, A. G.,
and Sonnenberg, A.
(1991)
Eur. J. Biochem.
199,
425-433[Medline]
[Order article via Infotrieve]
|
| 41.
|
Hogervorst, F.,
Kuikman, I.,
Noteboom, E.,
and Sonnenberg, A.
(1993)
J. Biol. Chem.
268,
18427-18430[Abstract/Free Full Text]
|
| 42.
|
Hogervorst, F.,
Admiraal, L. G.,
Niessen, C.,
Kuikman, I.,
Janssen, H.,
Daams, H.,
and Sonnenberg, A.
(1993)
J. Cell Biol.
121,
179-191[Abstract/Free Full Text]
|
| 43.
|
Tamura, R. N.,
Cooper, H. M.,
Collo, G.,
and Quaranta, V.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
10183-10187[Abstract/Free Full Text]
|
| 44.
|
Shaw, L. M.,
Turner, C. E.,
and Mercurio, A. M.
(1995)
J. Biol. Chem.
270,
23648-23652[Abstract/Free Full Text]
|
| 45.
|
Wei, J.,
Shaw, L. M.,
and Mercurio, A. M.
(1998)
J. Biol. Chem.
273,
5903-5907[Abstract/Free Full Text]
|
| 46.
|
Robinson, M. J.,
and Cobb, M. H.
(1997)
Curr. Opin. Cell Biol.
9,
180-186[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Schaeffer, H. J.,
and Weber, M. J.
(1999)
Mol. Cell. Biol.
19,
2435-2444[Free Full Text]
|
| 48.
|
Herlaar, E.,
and Brown, Z.
(1999)
Mol. Med. Today
5,
439-447[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Nakamura, K.,
Shirai, T.,
Morishita, S.,
Uchida, S.,
Saeki-Miura, K.,
and Makishima, F.
(1999)
Exp. Cell Res.
250,
351-363[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Oh, C. D.,
Chang, S. H.,
Yoon, Y. M.,
Lee, S. J.,
Lee, Y. S.,
Kang, S. S.,
and Chun, J. S.
(2000)
J. Biol. Chem.
275,
5613-5619[Abstract/Free Full Text]
|
| 51.
|
Yoon, Y. M., Oh, C. D.,
Kim, D. Y.,
Lee, Y. S.,
Park, J. W.,
Huh, T. L.,
Kang, S. S.,
and Chun, J. S.
(2000)
J. Biol. Chem.
275,
12353-12359[Abstract/Free Full Text]
|
| 52.
|
Descalzi Cancedda, F.,
Manduca, P.,
Tacchetti, C.,
Fossa, P.,
Quarto, R.,
and Cancedda, R.
(1988)
J. Cell Biol.
107,
2455-2463[Abstract/Free Full Text]
|
| 53.
|
Hamburger, V.,
and Hamilton, H. L.
(1992)
Dev. Dyn.
195,
231-272[Medline]
[Order article via Infotrieve]
|
| 54.
|
Fuerstenberg, S.,
Beug, H.,
Introna, M.,
Khazaie, K.,
Munoz, A.,
Ness, S.,
Nordstrom, K.,
Sap, J.,
Stanley, I.,
Zenke, M.,
et al..
(1990)
J. Virol.
64,
5891-5902[Abstract/Free Full Text]
|
| 55.
|
Delwel, G. O.,
Hogervorst, F.,
Kuikman, I.,
Paulsson, M.,
Timpl, R.,
and Sonnenberg, A.
(1993)
J. Biol. Chem.
268,
25865-25875[Abstract/Free Full Text]
|
| 56.
|
Argraves, W. S.,
Suzuki, S.,
Arai, H.,
Thompson, K.,
Pierschbacher, M. D.,
and Ruoslahti, E.
(1987)
J. Cell Biol.
105,
1183-1190[Abstract/Free Full Text]
|
| 57.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685[CrossRef][Medline]
[Order article via Infotrieve]
|
| 58.
|
Chang, S. H., Oh, C. D.,
Yang, M. S.,
Kang, S. S.,
Lee, Y. S.,
Sonn, J. K.,
and Chun, J. S.
(1998)
J. Biol. Chem.
273,
19213-19219[Abstract/Free Full Text]
|
| 59.
|
Zhen, X.,
Wei, L., Wu, Q.,
Zhang, Y.,
and Chen, Q.
(2000)
J. Biol. Chem.
29,
29
|
| 60.
|
Shaw, L. M.,
and Mercurio, A. M.
(1993)
J. Cell Biol.
123,
1017-1025[Abstract/Free Full Text]
|
| 61.
|
Shaw, L. M.,
and Mercurio, A. M.
(1994)
Mol. Biol. Cell
5,
679-690[Abstract]
|
| 62.
|
Swalla, B. J.,
and Solursh, M.
(1984)
Differentiation
26,
42-48[CrossRef][Medline]
[Order article via Infotrieve]
|
| 63.
|
Miyamoto, S.,
Teramoto, H.,
Gutkind, J. S.,
and Yamada, K. M.
(1996)
J. Cell Biol.
135,
1633-1642[Abstract/Free Full Text]
|
| 64.
|
Lin, T. H.,
Chen, Q.,
Howe, A.,
and Juliano, R. L.
(1997)
J. Biol. Chem.
272,
8849-8852[Abstract/Free Full Text]
|
| 65.
|
Short, S. M.,
Boyer, J. L.,
and Juliano, R. L.
(2000)
J. Biol. Chem.
275,
12970-12977[Abstract/Free Full Text]
|
| 66.
|
Aplin, A. E.,
Stewart, S. A.,
Assoian, R. K.,
and Juliano, R. L.
(2001)
J. Cell Biol.
153,
273-282[Abstract/Free Full Text]
|
| 67.
|
Maciera-Coelho, A.
(1973)
in
Tissue Culture: Methods and Applications
(Kruse, P. F., Jr.
, and Patterson, M. K., Jr., eds)
, pp. 412-422, Academic Press, New York
|
| 68.
|
Gimond, C.,
Baudoin, C.,
van der Neut, R.,
Kramer, D.,
Calafat, J.,
and Sonnenberg, A.
(1998)
J. Cell Biol.
143,
253-266[Abstract/Free Full Text]
|
| 69.
|
Cuenda, A.,
Rouse, J.,
Doza, Y. N.,
Meyer, R.,
Cohen, P.,
Gallagher, T. F.,
Young, P. R.,
and Lee, J. C.
(1995)
FEBS Lett.
364,
229-233[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. Wang, A. Woods, S. Sabari, L. Pagnotta, L.-A. Stanton, and F. Beier
RhoA/ROCK Signaling Suppresses Hypertrophic Chondrocyte Differentiation
J. Biol. Chem.,
March 26, 2004;
279(13):
13205 - 13214.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|